Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations

Overview of attention for article published in OncoTargets and therapy, July 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

patent: 1 patent

Citations

dimensions_citation: 64 Dimensions

Readers on

mendeley: 40 Mendeley

Summary Patents Dimensions citations

So far, Dimensions has found 64 publications that cite this research output.

64

The most recent citing publications are shown below. View all 64 publications that cite this research output on Dimensions.

Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations

Article in Frontiers in Immunology (May 2024)

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer

Article in Frontiers in Oncology (April 2024)

Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art

Article in Cancers (March 2024)